SCHEMBL11306

SCHEMBL11306

COc1ccc(-c2n[nH]c3ncnc(N)c23)cc1F

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SRC P12931 13/20 0.47
PIK3CD O00329 12/20 0.47
ABL1 P00519 10/20 0.47
EGFR P00533 9/20 0.47
HCK P08631 9/20 0.47
PIK3CA P42336 9/20 0.47
PIK3CB P42338 9/20 0.47
MTOR P42345 9/20 0.47
PIK3CG P48736 9/20 0.47
EPHB4 P54760 9/20 0.47
PRKDC P78527 9/20 0.47
KDR P35968 8/20 0.47
PI4KB Q9UBF8 8/20 0.47
KIT P10721 1/20 0.44
ALDH1A1 P00352 2/20 0.43
MEN1 O00255 1/20 0.43
NPC1 O15118 1/20 0.43
RAB9A P51151 1/20 0.43
KMT2A Q03164 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10811 0.90 SRC (0.57) SRCPIK3CDABL1EGFRHCK
SCHEMBL149180 0.88 PIK3CD (0.55) SRCPIK3CDABL1EGFRHCK
SCHEMBL217790 0.88 ABL1 (0.49) SRCPIK3CDABL1EGFRHCK
SCHEMBL13717800 0.87 CSNK1E (0.45) SRCPIK3CDABL1EGFRHCK
SCHEMBL13717774 0.85 PIK3CD (0.41) SRCPIK3CDABL1EGFRHCK
SCHEMBL19414295 0.85 SRC (0.47) SRCPIK3CDABL1EGFRHCK
SCHEMBL22075531 0.83 ALDH1A1 (0.40) SRCPIK3CDABL1EGFRHCK
SCHEMBL22692856 0.83 ERBB2 (0.50) SRCPIK3CDPIK3CAPIK3CBPIK3CG
SCHEMBL11975 0.83 PIK3CB (0.39) SRCPIK3CDABL1EGFRHCK
SCHEMBL16665685 0.83 PIK3CD (0.67) SRCPIK3CDABL1EGFRHCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113968861-B Compound with PI3K delta/BTK double-target-point activity and preparation method and application thereof 杭州医学院 2022-10-21 CN claimed
CN-113968861-A Compound with PI3K delta/BTK double-target-point activity and preparation method and application thereof 杭州医学院 2022-01-25 CN claimed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US claimed
US-12221448-B2 Selective PI3Kδ inhibitor and use thereof Tarapeutics Science Inc. (CN) 2025-02-11 US disclosed
US-20240360095-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2024-10-31 US disclosed
EP-3892619-B1 SELECTIVE PHOSPHATIDYLINOSITOL 3 KINASE (PI3K) INHIBITORS AND USE THEREOF TARAPEUTICS SCIENCE INC (CN) 2024-06-26 EP disclosed
EP-3892619-B1 SELECTIVE PHOSPHATIDYLINOSITOL 3 KINASE (PI3K) INHIBITORS AND USE THEREOF TARAPEUTICS SCIENCE INC (CN) 2024-06-26 EP disclosed
US-11858907-B2 Kinase modulators RHIZEN PHARMACEUTICALS AG (CH) 2024-01-02 US disclosed
CN-111269231-B Selective PI3K delta inhibitor and application thereof 安徽中科拓苒药物科学研究有限公司 2023-06-09 CN disclosed
CN-113968861-B Compound with PI3K delta/BTK double-target-point activity and preparation method and application thereof 杭州医学院 2022-10-21 CN disclosed
US-20220251092-A1 CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF Hangzhou Healzen Therapeutics Co., Ltd. (CN) 2022-08-11 US disclosed
US-20160318890-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2016-11-03 US disclosed
US-9421209-B2 Kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2016-08-23 US disclosed
EP-3050876-A2 KINASE MODULATORS Rhizen Pharmaceuticals S.A. (CH) 2016-08-03 EP disclosed
US-20150174131-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS AG (CH) 2015-06-25 US disclosed
US-9018375-B2 Substituted chromenes as kinase modulators RHIZEN PHARMACEUTICALS SA (CH) 2015-04-28 US disclosed
US-20140080827-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2014-03-20 US disclosed
US-8642607-B2 4H-chromen-4-one compounds as modulators of protein kinases RHIZEN PHARMACEUTICALS SA (CH) 2014-02-04 US disclosed
US-20120059001-A1 NOVEL KINASE MODULATORS INCOZEN THERAPEUTICS PVT. LTD. (IN) 2012-03-08 US disclosed
US-20110118257-A1 NOVEL KINASE MODULATORS RHIZEN PHARMACEUTICALS SA (CH) 2011-05-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150174131-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-20240360095-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-20140080827-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-20110118257-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-11858907-B2 Kinase modulators RPS6KA1, RPS6KA2, PRKAR2A SRC 110/4885PIK3CD 103/4885ABL1 258/4885
US-20160318890-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-12221448-B2 Selective PI3Kδ inhibitor and use thereof PIK3CA, PIK3CD, PIK3R2 SRC 99/4885PIK3CD 2/4885ABL1 199/4885
US-20120059001-A1 NOVEL KINASE MODULATORS PRKCA, PRKCH, PRKCB SRC 314/4885PIK3CD 70/4885ABL1 465/4885
US-20220251092-A1 CASEIN KINASE 1EPSILON INHIBITOR, PHARMACEUTICAL COMPOSITION AND APPLICATION THEREOF CSNK1E, CSNK1A1, CSNK1G1 SRC 100/4885PIK3CD 439/4885ABL1 402/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.